Sakhanda Wire
NVDA $153.59 -1.64% MSFT $507.00 -2.12% GOOGL $279.98 -1.32% META $619.94 -1.03% AMZN $256.62 -0.44%
← Back to the news

AI-designed drug linked to younger biological-age markers in early trial

An analysis published in Nature Biotechnology suggests that rentosertib, an AI-designed drug from Insilico Medicine, may change markers associated with biological aging. The medicine was developed for idiopathic pulmonary fibrosis (IPF), a disease that scars lung tissue. Researchers examined blood samples from a 42-patient trial using six independent AI aging clocks, which estimate biological age from protein patterns.

All six models assigned treated patients a lower predicted biological age than those receiving placebo. The largest difference appeared around week four, generally at three to four years, while one clock indicated a gap of up to six years. The findings do not show that patients physically became younger; they show that their blood-protein patterns shifted in a direction the models associate with younger age.

Experts described the result as promising but preliminary. They cited the small sample, uncertainty about the reliability of biological clocks and the absence of testing in healthy people. The changes could partly reflect improved lung function, although the dose producing the strongest aging-clock effect differed from the dose that helped lung function most. Insilico identified TNIK as a target using AI systems and has advanced rentosertib to a Phase III IPF trial.

Written by Sakhanda Wire AI from reporting by The Decoder. Facts, quotes and full context are in the original article below.

Originally published by The Decoder on

Read the original on The Decoder ↗

The reporting and the image belong to The Decoder and are credited and linked above; the text on this page is Sakhanda Wire's own summary.

← Back to the news

More stories

All the latest news